Wenbin Jiang - Jul 22, 2021 Form 3 Insider Report for Cytek BioSciences, Inc. (CTKB)

Role
President and CEO, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
Stock symbol
CTKB
Transactions as of
Jul 22, 2021
Transactions value $
$0
Form type
3
Date filed
7/22/2021, 08:57 PM
Next filing
Feb 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTKB Common Stock 7.85M Jul 22, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTKB Series A Preferred Stock Jul 22, 2021 Common Stock 2.67M See footnote F1, F2
holding CTKB Stock Option (Right to Buy) Jul 22, 2021 Common Stock 66.7K $0.25 Direct
holding CTKB Stock Option (Right to Buy) Jul 22, 2021 Common Stock 107K $0.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
F2 These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any.
F3 The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 24, 2021; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.

Remarks:

Exhibit 24 - Power of Attorney